دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Exposure to Cardiology as a Strategy to Increase the Number of Black Men in Medicine
Mridula Nadamuni, Nicole E. Minniefield, Dale O. Okorodudu
doi : 10.1161/CIRCULATIONAHA.120.051578
Circulation. 2021;143:513–515
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M.Y. Lee, Katriona J.M. Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T. Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F. Docherty, John G. Dreisbach, Catherine Labinjoh, Ninian N. Lang, Vera Lennie, Alex McConnachie, Clare L. Murphy, Colin J. Petrie, John R. Petrie, Iain A. Speirits, Steven Sourbron, Paul Welsh, Rosemary Woodward, Aleksandra Radjenovic, Patrick B. Mark, John J.V. McMurray, Pardeep S. Jhund, Mark C. Petrie, Naveed Sattar See fewer authors
doi : 10.1161/CIRCULATIONAHA.120.052186
Circulation. 2021;143:516–525
Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain.
Biostatistics Versus Pathophysiology
Jay N. Cohn
doi : 10.1161/CIRCULATIONAHA.120.052585
Circulation. 2021;143:526–527
Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction
Are Annes?nn Kalstad, Peder Langeland Myhre, Kristian Laake, Sjur Hansen Tveit, Erik Berg Schmidt, Paal Smith, Dennis Winston Trygve Nilsen, Arnljot Tveit, Morten Wang Fagerland, Svein Solheim, Ingebj?rg Seljeflot, Harald Arnesen, and On behalf of the OMEMI Investigators
doi : 10.1161/CIRCULATIONAHA.120.052209
Circulation. 2021;143:528–539
High intake of marine n-3 polyunsaturated fatty acids (PUFA) has been associated with reduced risk of cardiovascular events; however, this has not been confirmed in patients with a recent acute myocardial infarction (AMI). Elderly patients are at particularly increased cardiovascular risk after myocardial infarction, but few trials address this group specifically. Omega-3 fatty acids hold the potential to reduce cardiovascular events with limited adverse effects in this vulnerable group. The hypothesis was that daily addition of 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up.
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph, George L. Bakris, and For the FIDELIO-DKD Investigators
doi : 10.1161/CIRCULATIONAHA.120.051898
Circulation. 2021;143:540–552
The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) evaluated the effect of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with optimized renin–angiotensin system blockade. Compared with placebo, finerenone reduced the composite kidney and cardiovascular outcomes. We report the effect of finerenone on individual cardiovascular outcomes and in patients with and without history of atherosclerotic cardiovascular disease (CVD).
Myocardial Injury in Severe COVID-19 Compared With Non–COVID-19 Acute Respiratory Distress Syndrome
Thomas S. Metkus, Lori J. Sokoll, Andreas S. Barth, Matthew J. Czarny, Allison G. Hays, Charles J. Lowenstein, Erin D. Michos, Eric P. Nolley, Wendy S. Post, Jon R. Resar, David R. Thiemann, Jeffrey C. Trost, Rani K. Hasan
doi : 10.1161/CIRCULATIONAHA.120.050543
Circulation. 2021;143:553–565
Knowledge gaps remain in the epidemiology and clinical implications of myocardial injury in coronavirus disease 2019 (COVID-19). We aimed to determine the prevalence and outcomes of myocardial injury in severe COVID-19 compared with acute respiratory distress syndrome (ARDS) unrelated to COVID-19.
Endothelial Cell Indoleamine 2, 3-Dioxygenase 1 Alters Cardiac Function After Myocardial Infarction Through Kynurenine
Nada Joe Melhem, Mouna Chajadine, Ingrid Gomez, Kiave-Yune Howangyin, Marion Bouvet, Camille Knosp, Yanyi Sun, Marie Rouanet, Ludivine Laurans, Olivier Cazorla, Mathilde Lemitre, José Vilar, Ziad Mallat, Alain Tedgui, Hafid Ait-Oufella, Jean-Sébastien Hulot, Jacques Callebert, Jean-Marie Launay, Jeremy Fauconnier, Jean-Sébastien Silvestre, Soraya Taleb
doi : 10.1161/CIRCULATIONAHA.120.050301
Circulation. 2021;143:566–580
Ischemic cardiovascular diseases, particularly acute myocardial infarction (MI), is one of the leading causes of mortality worldwide. Indoleamine 2, 3-dioxygenase 1 (IDO) catalyzes 1 rate-limiting step of L-tryptophan metabolism, and emerges as an important regulator of many pathological conditions. We hypothesized that IDO could play a key role to locally regulate cardiac homeostasis after MI.
Healthy Coronary Endothelial Cells, Happy Cardiomyocytes
Yajing Wang, Xinliang Ma
doi : 10.1161/CIRCULATIONAHA.120.052535
Circulation. 2021;143:581–582
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Dominick J. Angiolillo, Deepak L. Bhatt, Christopher P. Cannon, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Christopher B. Granger, David R. Holmes, Renato D. Lopes, Roxana Mehran, David J. Moliterno, Matthew J. Price, Jacqueline Saw, Jean-Francois Tanguay, David P. Faxon
doi : 10.1161/CIRCULATIONAHA.120.050438
Circulation. 2021;143:583–596
A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing PCI require oral anticoagulation for the prevention of cardiac thromboembolism and dual antiplatelet therapy for the prevention of coronary thrombotic complications. The combination of oral anticoagulation and dual antiplatelet therapy substantially increases the risk of bleeding. Over the last decade, a series of North American Consensus Statements on the Management of Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention have been reported. Since the last update in 2018, several pivotal clinical trials in the field have been published. This document provides a focused updated of the 2018 recommendations. The group recommends that in patients with atrial fibrillation undergoing PCI, a non–vitamin K antagonist oral anticoagulant is the oral anticoagulation of choice. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor should be given to all patients during the peri-PCI period (during inpatient stay, until time of discharge, up to 1 week after PCI, at the discretion of the treating physician), after which the default strategy is to stop aspirin and continue treatment with a P2Y12 inhibitor, preferably clopidogrel, in combination with a non–vitamin K antagonist oral anticoagulant (ie, double therapy). In patients at increased thrombotic risk who have an acceptable risk of bleeding, it is reasonable to continue aspirin (ie, triple therapy) for up to 1 month. Double therapy should be given for 6 to 12 months with the actual duration depending on the ischemic and bleeding risk profile of the patient, after which patients should discontinue antiplatelet therapy and receive oral anticoagulation alone.
From the Literature
Tracy Hampton
doi : 10.1161/CIRCULATIONAHA.120.053303
Circulation. 2021;143:597–598
Bizarre Downsloping ST Segment Elevation Challenge
Ilias Karabinos, Panagiota Kostaki, Zois Panagopoulos
doi : 10.1161/CIRCULATIONAHA.120.052862
Circulation. 2021;143:599–601
Gradient of Risk and Associations With Cardiovascular Efficacy of Ertugliflozin by Measures of Kidney Function
David Z.I. Cherney, Darren K. McGuire, Bernard Charbonnel, Francesco Cosentino, Richard Pratley, Samuel Dagogo-Jack, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Chih-Chin Liu, Christopher P. Cannon, and On behalf of the VERTIS CV Investigators
doi : 10.1161/CIRCULATIONAHA.120.051901
Circulation. 2021;143:602–605
Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy
Sara Saberi, Nuno Cardim, Mohamad Yamani, Jeanette Schulz-Menger, Wanying Li, Victoria Florea, Amy J. Sehnert, Raymond Y. Kwong, Michael Jerosch-Herold, Ahmad Masri, Anjali Owens, Neal K. Lakdawala, Christopher M. Kramer, Mark Sherrid, Tim Seidler, Andrew Wang, Farbod Sedaghat-Hamedani, Benjamin Meder, Ofer Havakuk, Daniel Jacoby
doi : 10.1161/CIRCULATIONAHA.120.052359
Circulation. 2021;143:606–608
COVID-19 Myocardial Pathology Evaluation in Athletes With Cardiac Magnetic Resonance (COMPETE CMR)
Daniel E. Clark, Amar Parikh, Jeffrey M. Dendy, Alex B. Diamond, Kristen George-Durrett, Frank A. Fish, James C. Slaughter, Warne Fitch, Sean G. Hughes, Jonathan H. Soslow
doi : 10.1161/CIRCULATIONAHA.120.052573
Circulation. 2021;143:609–612
Letter by Kessler et al Regarding Article, “Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52?816 Patients From 12 Randomized Trials”
Thorsten Kessler, Salvatore Cassese, Adnan Kastrati
doi : 10.1161/CIRCULATIONAHA.120.049650
Circulation. 2021;143:e230–e231
Letter by Ferracane et al Regarding Article, “Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52?816 Patients From 12 Randomized Trials”
Elisa Ferracane, Laura Bartoli, Andrea Messori
doi : 10.1161/CIRCULATIONAHA.120.050472
Circulation. 2021;143:e232–e233
Letter by Alkhalil and Kuzemczak Regarding Article, “Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52?816 Patients From 12 Randomized Trials”
Mohammad Alkhalil, Micha? Kuzemczak
doi : 10.1161/CIRCULATIONAHA.120.050967
Circulation. 2021;143:e234–e235
Response by Navarese et al to Letters Regarding Article, “Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52?816 Patients From 12 Randomized Trials”
Eliano P. Navarese, Safi U. Khan, Stefan James
doi : 10.1161/CIRCULATIONAHA.120.051630
Circulation. 2021;143:e236–e237
Correction to: COVID-19 Myocardial Pathology Evaluation in Athletes with Cardiac Magnetic Resonance (COMPETE CMR)
doi : 10.1161/CIR.0000000000000957
Circulation. 2021;143:e238
